Current Oncology Reports

, Volume 11, Issue 2, pp 125–131 | Cite as

The chemokine receptors CXCR4 and CXCR3 in cancer



Chemokines comprise a superfamily of at least 46 cytokines that were initially described based on their ability to bind to 18 to 22 G protein-coupled receptors to induce the directed migration of leukocytes to sites of inflammation or injury. In addition to mediating cellular migration, chemokine/chemokine receptor pairs have been shown to affect many cellular functions, including survival, adhesion, invasion, and proliferation, and to regulate circulating chemokine levels. Most malignancies also express one or more chemokine receptors. Early studies established a role for CXCR4 and CXCR7 in mediating breast cancer metastasis, but other chemokine receptors, including CXCR3, now are implicated in several malignancies as biomarkers of tumor behavior as well as potential therapeutic targets. This review summarizes our current understanding regarding the contribution of CXCR4 and CXCR3 to tumor behavior and how receptor expression is regulated, transduces intracellular signals, and contributes at the molecular level to tumor behavior. It also describes recent therapeutic approaches that target these receptors or their ligands.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Graham GJ, Nibbs RJ: Lukacs NW. Totowa, NJ: Humana Press; 2007:31–54.CrossRefGoogle Scholar
  2. 2.
    Muller A, Homey B, Soto H, et al.: Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50–56.PubMedCrossRefGoogle Scholar
  3. 3.
    Smith MCP, Luker KE, Gargow JR, et al.: CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004, 64:8604–8612.PubMedCrossRefGoogle Scholar
  4. 4.
    Balkwill F: The significance of the cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 2004, 14:171–179.PubMedCrossRefGoogle Scholar
  5. 5.
    Scotten CJ, Wilson JL, Scott K, et al.: Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 2002, 62:5930–5938.Google Scholar
  6. 6.
    Tamamura H, Hori A, Kanzaki N, et al.: T140 analogs as CXCR4 antagonists identified as antimetastatic agents in the treatment of breast cancer. FEBS Lett 2003, 550:79–83.PubMedCrossRefGoogle Scholar
  7. 7.
    Bertolini F, Dell’Agnola C, Mancuso P, et al.: CXCR4 neutralization a novel therapeutic approach for non-Hodgkin’s lymphoma. Cancer Res 2002, 62:3106–3112.PubMedGoogle Scholar
  8. 8.
    Murakami T, Maki W, Cardones AR, et al.: Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res 2002, 62:7328–7334.PubMedGoogle Scholar
  9. 9.
    Ben-Baruch A: Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastasis 2008, 25:345–356.PubMedCrossRefGoogle Scholar
  10. 10.
    Zagzag D, Lukyanov Y, Lan L, et al.: Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 2006, 86:1221–1232.PubMedCrossRefGoogle Scholar
  11. 11.
    Akashi T, Koizumi K, Nagakawa O, et al.: Androgen receptor negatively influences the expression of chemokine receptors (CXCR4, CCR1) and ligand-mediated migration in prostate cancer DU-145. Oncol Rep 2006, 16:831–836.PubMedGoogle Scholar
  12. 12.
    Sengupta S, Schiff R, Katzenellenbogen BS: Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER overexpressing, estrogen receptor-positive breast cancer cells. Breast Cancer Res Treat 2008 Sep 19 [Epub ahead of print].Google Scholar
  13. 13.
    Holland JD, Kochetkova M, Akekawatchai C, et al.: Differential functional activation of chemokine receptor CXCR4 is mediated by G proteins in breast cancer. Cancer Res 2006, 66:4117–4124.PubMedCrossRefGoogle Scholar
  14. 14.
    Serrati S, Margheri F, Fibbi G, et al.: Endothelial cells and normal breast epithelial cells enhance invasion of breast carcinoma cells by CXCR4-dependent up-regulation of urokinase-type plasminogen activator receptor (uPAR, CD87) expression. J Pathol 2008, 214:545–554.PubMedCrossRefGoogle Scholar
  15. 15.
    Akekawtchai C, Holland JD, Kochetkova M, et al.: Transactivation of CXCR4 by the insulin-like growth factor-1 receptor (IGF-1R) in human MDA-MB-231 breast cancer epithelial cells. J Biol Chem 2005, 280:39701–39708.CrossRefGoogle Scholar
  16. 16.
    Chinni SR, Yamamoto H, Dong Z, et al.: CXC12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol Cancer Res 2008, 6:446–457.PubMedCrossRefGoogle Scholar
  17. 17.
    Liang Z, Wu T, Lou H, et al.: Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res 2004, 64:4302–4308.PubMedCrossRefGoogle Scholar
  18. 18.
    Yoon Y, Liang Z, Zhang X, et al.: CXC chemokine receptor-4-antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models. Cancer Res 2007, 15:7518–7524.CrossRefGoogle Scholar
  19. 19.
    Rubin JB, Kung AL, Klein RS, et al.: A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A 2003, 100:13513–13518.PubMedCrossRefGoogle Scholar
  20. 20.
    Yang L, Jackson E, Woerner BM, et al.: Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo. Cancer Res 2007, 67:651–658.PubMedCrossRefGoogle Scholar
  21. 21.
    Kim SY, Lee CH, Midura BV, et al.: Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis 2008, 25:201–211.PubMedCrossRefGoogle Scholar
  22. 22.
    Lasagni L, Francalanci M, Annunziato F, et al.: An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 2003, 197:1537–1549.PubMedCrossRefGoogle Scholar
  23. 23.
    Ehlert JE, Addison CA, Burdick MD, et al.: Identification and partial characterization of a variant of human CXR3 generated by posttranscriptional exon skipping. J Immunol 2004, 173:6234–6240.PubMedGoogle Scholar
  24. 24.
    Monteagudo C, Martin JM, Jorda E, Llombart-Bosch A: CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathologic prognostic factors. J Clin Pathol 2007, 60:596–599.PubMedCrossRefGoogle Scholar
  25. 25.
    Kawada K, Hosogi H, Sonoshita M, et al.: Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene 2007, 26:4679–4688.PubMedCrossRefGoogle Scholar
  26. 26.
    Ma X, Norsworthy K, Kundu N, et al.: CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Mol Cancer Ther, in press.Google Scholar
  27. 27.
    Jones D, Benjamin RJ, Shahsafaei A, Dorfman DM: The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood 2000, 95:627–632.PubMedGoogle Scholar
  28. 28.
    Klatte T, Seligson DB, Leppert JT, et al.: The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma. J Urol 2008, 179:61–66.PubMedCrossRefGoogle Scholar
  29. 29.
    Kawada K, Sonoshita M, Sakashita H: Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res 2004, 64:4010–4017.PubMedCrossRefGoogle Scholar
  30. 30.
    Goldberg-Bittman L, Neumark E, Sagi-Assif O, et al.: The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines. Immunol Lett 2004, 92:171–178.PubMedCrossRefGoogle Scholar
  31. 31.
    Goldberg-Bittman L, Sagi-Assif O, Meshel T, et al.: Cellular characteristics of neuroblastoma cells: regulation by the ELR-CXC chemokine CXCL10 and expression of a CXCR3-like receptor. Cytokine 2005, 29:105–117.PubMedCrossRefGoogle Scholar
  32. 32.
    Datta D, Flaxenburg JA, Laxmanan S, et al.: Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Res 2006, 66:9509–9518.PubMedCrossRefGoogle Scholar
  33. 33.
    Walser TC, Rifat S, Ma X, et al.: Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res 2006, 66:7701–7707.PubMedCrossRefGoogle Scholar
  34. 34.
    Zipin-Roitman A, Meshel T, Sagi-Assif O, et al.: CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res 2007, 67:3396–3405.PubMedCrossRefGoogle Scholar
  35. 35.
    Luster AD, Leder P: IP-10, a C-X-C chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med 1993, 178:1057–1065.PubMedCrossRefGoogle Scholar
  36. 36.
    Sgadari C, Angiolillo AL, Cherney BW, et al.: Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci U S A 1996, 93:13791–13796.PubMedCrossRefGoogle Scholar
  37. 37.
    Dorsey R, Kundu N, Yang Q, et al.: Immunotherapy with interleukin-10 depends on the CXC chemokines inducible protein-10 and monokine induced by IFN-gamma. Cancer Res 2002, 62:2606–2610.PubMedGoogle Scholar
  38. 38.
    Walser TC, Ma X, Kundu N, et al.: Immune-mediated modulation of breast cancer growth and metastasis by the chemokine Mig (CXCL9) in a murine model. J Immunother 2007, 30:490–498.PubMedCrossRefGoogle Scholar
  39. 39.
    Winter D, Moser J, Kriehuber E, et al.: Down-modulation of CXCR3 surface expression and function in CD8+ T cells from cutaneous T cell lymphoma patients. J Immunol 2007, 179:4272–4282.PubMedGoogle Scholar

Copyright information

© Current Medicine Group LLC 2009

Authors and Affiliations

  1. 1.University of Maryland Marlene and Stewart Greenebaum Cancer Center and Department of PathologyUniversity of Maryland School of MedicineBaltimoreUSA

Personalised recommendations